ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis

This publication has 33 references indexed in Scilit:

• The function of ADAMTS13 in thrombogenesis in vivo: insights from mutant mice
  International Journal of Hematology, 2010
• Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells
  Journal of Thrombosis and Haemostasis, 2008
• Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor
  American Journal of Physiology-Renal Physiology, 2008
• The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases
  Critical Reviews in Biochemistry and Molecular Biology, 2007
• ADAMTS‐13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences
  Journal of Thrombosis and Haemostasis, 2006
• ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions
  Blood, 2002
• Purification of human von Willebrand factor–cleaving protease and its identification as a new member of the metalloproteinase family
  Blood, 2001
• Partial amino acid sequence of purified von Willebrand factor–cleaving protease
  Blood, 2001
• The Cysteine-Rich Domain of Human Adam 12 Supports Cell Adhesion through Syndecans and Triggers Signaling Events That Lead to β1 Integrin–Dependent Cell Spreading
  Journal of Cell Biology, 2000
• A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.
  Proceedings of the National Academy of Sciences, 1990